Metrics as of 10/16/2026, 11:48 PM (Berlin time), refresh in progress.
Veracyte Stock
Veracyte, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Marc Stapley
- Employees
- 755
- Market cap
- $3.5 B
- IPO
- 29/10/2013
Veracyte, Inc. operates as a specialized diagnostics provider within the Healthcare / Medical - Diagnostics & Research sector and is based in the United States. The company utilizes genomic testing methods to support cancer diagnostics, with a portfolio that includes various applications for examining thyroid,…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Veracyte stock: price history
1D
-2.9%
1W
-4.7%
1M
+12.0%
6M
+27.6%
YTD
+2.4%
1Y
+20.4%
2Y
+24.2%
5Y
-4.5%
10Y
+468.9%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~71% stronger price swings than usual
Veracyte stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Veracyte, Inc. is a diagnostics company specializing in genomic testing for the diagnosis of various cancer types. Its core business encompasses highly specialized assays such as Afirma sequencing for thyroid nodules, Decipher for prostate cancer, and Prosigna for breast cancer, as well as the Percepta test for lung cancer. Revenue streams are generated almost exclusively through the testing business, representing a high proportion of recurring transactions. The company also offers analytical services through its nCounter system. The primary focus is on the US market.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about Veracyte
Analyst assessment of Veracyte
PRICE TARGET LOW
US$44.00
CONSENSUS
US$57.43
MEDIAN
US$55.00
PRICE TARGET HIGH
US$69.00
0
STRONG BUY
15
BUY
6
HOLD
1
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 15/09/2026
Veracyte stock metrics
P/E
29.94
P/B
2.47
EV/EBITDA
24.71
RETURN ON EQUITY
1.8%
NET MARGIN
17.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.4%
FLOAT SHARES
79,882,662
AVG. DAILY VOLUME (30D)
1,413,048
Insider transactions (SEC)
Leite John
Holstein Jens
Febbo Phillip G.
Febbo Phillip G.
Febbo Phillip G.
Attention
Price since yesterday: -2.9%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Veracyte stock
What does Veracyte do?
Veracyte, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Marc Stapley, the company employs around 755 people.
The IPO was on 29/10/2013; the stock trades on NASDAQ under the ticker VCYT.
What do analysts say about Veracyte stock?
22 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$57.43, ranging from US$44.00 to US$69.00, with a median of US$55.00.
This is an external assessment, not a statement by Market Jury.
When does Veracyte report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 71% stronger than usual.
Does Veracyte pay a dividend?
No, Veracyte currently does not pay a dividend.
Which stocks are comparable to Veracyte?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Veracyte stock analyzed?
Clicking "Analyze stock" lets five strategies assess Veracyte against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.